Clinical Multigene Testing for Prostate Cancer

Epidemiology of prostate cancer.

World J Oncol. 10: 63-89

Cancer stat facts: prostate cancer.

()Siegel R.L. Miller K.D. Jemal A.

Cancer statistics, 2020.

CA Cancer J Clin. 70: 7-30

Cancer facts and figures.

The heritability of human disease: estimation, uses and abuses.

Nat Rev Genet. 14: 139-149Lichtenstein P. Holm N.V. Verkasalo P.K. et al.

Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland.

N Engl J Med. 343: 78-85Mucci L.A. Hjelmborg J.B. Harris J.R. et al.

Familial risk and heritability of cancer among Twins in Nordic Countries.

JAMA. 315: 68-76Hjelmborg J.B. Scheike T. Holst K. et al.

The heritability of prostate cancer in the Nordic Twin Study of Cancer.

Cancer Epidemiol Biomarkers Prev. 23: 2303-2310Giri V.N. Knudsen K.E. Kelly W.K. et al.

Implementation of germline testing for prostate cancer: philadelphia prostate cancer consensus conference 2019.

J Clin Oncol. ()Pritchard C.C. Mateo J. Walsh M.F. et al.

Inherited DNA-repair gene mutations in men with metastatic prostate cancer.

N Engl J Med. 375: 443-453Mateo J. Carreira S. Sandhu S. et al.

DNA-repair defects and olaparib in metastatic prostate cancer.

N Engl J Med. 373: 1697-1708Kote-Jarai Z. Leongamornlert D. Saunders E. et al.

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Br J Cancer. 105: 1230-1234Ewing C.M. Ray A.M. Lange E.M. et al.

Germline mutations in HOXB13 and prostate-cancer risk.

N Engl J Med. 366: 141-149Mersch J. Jackson M.A. Park M. et al.

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.

Cancer. 121: 269-275Van Asperen C.J. Brohet R.M. Meijers-Heijboer E.J. et al.

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.

J Med Genet. 42: 711-719Gallagher D.J. Gaudet M.M. Pal P. et al.

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Clin Cancer Res. 16: 2115-2121Moran A. O’Hara C. Khan S. et al.

Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations.

Fam Cancer. 11: 235-242Roed Nielsen H. Petersen J. Therkildsen C. et al.

Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.

Acta Oncol. 55: 38-44Agalliu I. Karlins E. Kwon E.M. et al.

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.

Br J Cancer. 97: 826-831Nyberg T. Frost D. Barrowdale D. et al.

Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Eur Urol. 77: 24-35

Cancer risks in BRCA2 mutation carriers.

J Natl Cancer Inst. 91: 1310-1316Kirchhoff T. Kauff N.D. Mitra N. et al.

BRCA mutations and risk of prostate cancer in Ashkenazi Jews.

Clin Cancer Res. 10: 2918-2921Breyer J.P. Avritt T.G. McReynolds K.M. et al.

Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.

Cancer Epidemiol Biomarkers Prev. 21: 1348-1353Karlsson R. Aly M. Clements M. et al.

A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.

Eur Urol. 65: 169-176Kote-Jarai Z. Mikropoulos C. Leongamornlert D.A. et al.

Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

Ann Oncol. 26: 756-761Xu J. Lange E.M. Lu L. et al.

HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).

Hum Genet. 132: 5-14Hoffmann T.J. Sakoda L.C. Shen L. et al.

Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort.

PLoS Genet. 11: e1004930Leongamornlert D. Mahmud N. Tymrakiewicz M. et al.

Germline BRCA1 mutations increase prostate cancer risk.

Br J Cancer. 106: 1697-1701Grindedal E.M. Møller P. Eeles R. et al.

Germ-line mutations in mismatch repair genes associated with prostate cancer.

Cancer Epidemiol Biomarkers Prev. 18: 2460-2467Raymond V.M. Mukherjee B. Wang F. et al.

Elevated risk of prostate cancer among men with Lynch syndrome.

J Clin Oncol. 31: 1713-1718Bauer C.M. Ray A.M. Halstead-Nussloch B.A. et al.

Hereditary prostate cancer as a feature of Lynch syndrome.

Fam Cancer. 10: 37-42Ryan S. Jenkins M.A. Win A.K.

Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis.

Cancer Epidemiol Biomarkers Prev. 23: 437-449Rosty C. Walsh M.D. Lindor N.M. et al.

High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.

Fam Cancer. 13: 573-582Thompson D. Easton D.F. Breast Cancer Linkage Consortium

Cancer incidence in BRCA1 mutation carriers.

J Natl Cancer Inst. 94: 1358-1365

CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.

Int J Clin Exp Med. 8: 15708Meyer A. Wilhelm B. Dörk T. et al.

ATM missense variant P1054R predisposes to prostate cancer.

Radiother Oncol. 83: 283-288Cybulski C. Wokołorczyk D. Kluźniak W. et al.

An inherited NBN mutation is associated with poor prognosis prostate cancer.

Br J Cancer. 108: 461-468Hale V. Weischer M. Park J.Y.

CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

Prostate Cancer. 2014: 294575Cybulski C. Górski B. Debniak T. et al.

NBS1 is a prostate cancer susceptibility gene.

Cancer Res. 64: 1215-1219Rusak B. Kluźniak W. Wokołorczykv D. et al.

Inherited NBN mutations and prostate cancer risk and survival.

Cancer Res Treat. 51: 1180-1187Angèle S. Falconer A. Edwards S.M. et al.

ATM polymorphisms as risk factors for prostate cancer development.

Br J Cancer. 91: 783-787Wu Y. Yu H. Zheng S.L. et al.

A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Prostate. 78: 607-615Akbari M.R. Wallis C.J.D. Toi A. et al.

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.

Br J Cancer. 111: 1238-1240Tryggvadóttir L. Vidarsdóttir L. Thorgeirsson T. et al.

Prostate cancer progression and survival in BRCA2 mutation carriers.

J Natl Cancer Inst. 99: 929-935Thorne H. Willems A.J. Niedermayr E. et al.

Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.

Cancer Prev Res. 4: 1002-1010Na R. Zheng S.L. Han M. et al.

Germline Mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.

Eur Urol. 71: 740-747Leongamornlert D. Saunders E. Dadaev T. et al.

Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.

Br J Cancer. 110: 1663-1672Jeggo P.A. Pearl L.H. Carr A.M.

DNA repair, genome stability and cancer: a historical perspective.

Nat Rev Cancer. 16: 35-42Ratta R. Guida A. Scotté F. et al.

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.

Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-020-0233-3Mateo J. Porta N. Bianchini D. et al.

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Lancet Oncol. 21: 162-174Pomerantz M.M. Spisák S. Jia L. et al.

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.

Cancer. 123: 3532-3539Le D.T. Durham J.N. Smith K.N. et al.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Science. 357: 409-413Abida W. Cheng M.L. Armenia J. et al.

Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade.

JAMA Oncol. 5: 471-478Carlo M.I. Giri V.N. Paller C.J. et al.

Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: a white paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

JCO Precision Oncol. 2: 1-14Gillessen S. Attard G. Beer T.M. et al.

Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017.

Eur Urol. 73: 178-211Giri V.N. Knudsen K.E. Kelly W.K. et al.

Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017.

J Clin Oncol. 36: 414-424

Leveraging clinical tumor-profiling programs to achieve comprehensive germline-inclusive precision cancer medicine.

JCO Precision Oncol. : 1-3

How far do we go with genetic evaluation? gene, panel, and tumor testing.

Am Soc Clin Oncol Educ Book. 35: e72-e78Susswein L.R. Marshall M.L. Nusbaum R. et al.

Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.

Genet Med. 18: 823-832Xue Y. Ankala A. Wilcox W.R. et al.

Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing.

Genet Med. 17: 444-451Jamal S.M. Yu J.-H. Chong J.X. et al.

Practices and policies of clinical exome sequencing providers: analysis and implications.

Am J Med Genet A. 161A: 935-950

Considerations of multigene test findings among men with prostate cancer - knowns and unknowns.

Can J Urol. 26: 14-16Giri V.N. Obeid E. Gross L. et al.

Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation.

JCO Precision Oncol. : 1-17Nicolosi P. Ledet E. Yang S. et al.

Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines.

JAMA Oncol. 5: 523-528Pritzlaff M. Tian Y. Reineke P. et al.

Diagnosing hereditary cancer predisposition in men with prostate cancer.

Genet Med. https://doi.org/10.1038/s41436-020-0830-5Cox D.M. Nelson K.L. Clytone M. et al.

Hereditary cancer screening: case reports and review of literature on ten Ashkenazi Jewish founder mutations.

Mol Genet Genomic Med. 6: 1236-1242Nielsen M. Infante E. Brand R.

MUTYH polyposis.

in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews®. University of Washington, SeattleLubin I.M. Caggana M. Constantin C. et al.

Ordering molecular genetic tests and reporting results: practices in laboratory and clinical settings.

J Mol Diagn. 10: 459-468Bentley A.R. Callier S. Rotimi C.N.

Diversity and inclusion in genomic research: why the uneven progress?.

J Community Genet. 8: 255-266

A scientometric review of genome-wide association studies.

Commun Biol. 2: 9Hamilton J.G. Lobel M. Moyer A.

Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review.

Health Psychol. 28: 510Stanislaw C. Xue Y. Wilcox W.R.

Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing.

Cancer Biol Med. 13: 55-67Manolio T.A. Chisholm R.L. Ozenberger B. et al.

Implementing genomic medicine in the clinic: the future is here.

Genet Med. 15: 258-267

The impact of hereditary cancer gene panels on clinical care and lessons learned.

Cold Spring Harb Mol Case Stud. 3Lu C.Y. Loomer S. Ceccarelli R. et al.

Insurance coverage policies for pharmacogenomic and multi-gene testing for cancer.

J Pers Med. 8Roberts M.C. Kurian A.W. Petkov V.I.

Uptake of the 21-gene assay among women with node-positive, hormone receptor-positive breast cancer.

J Natl Compr Canc Netw. 17: 662-668

The Genetic Information Nondiscrimination Act of 2008.

() ()

Genetic information, non-discrimination, and privacy protections in genetic counseling practice.

J Genet Couns. 23: 891-902Wagner C. Murphy L. Harkenrider J. et al.

Genesurance counseling: patient perspectives.

J Genet Couns. 27: 814-822Penon-Portmann M. Chang J. Cheng M. et al.

Genetics workforce: distribution of genetics services and challenges to health care in California.

Genet Med. 22: 227-231George S. Duran N. Norris K.

A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders.

Am J Public Health. 104: e16-e31

Metastatic prostate cancer project.

() ()

留言 (0)

沒有登入
gif